Medindia

X

Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis

by Medindia Content Team on  July 3, 2005 at 3:10 PM General Health News   - G J E 4
Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis
Recently the Food and Drug Administration (FDA) issued a public health advisory to inform patients and health care providers about the suspended marketing of Tysabri (nataluzimab) the drug meant to treat relapsing forms of multiple sclerosis (MS) which was approved by the FDA in 2004.

FDA supports the decision to voluntarily suspend marketing of the drug as well as the use of the product in clinical trials. However, it is believed that the drug has a promising role to play in treating multiple sclerosis.

Patients being treated with Tysabri have been asked to contact their physician to discuss appropriate alternative treatments while the reports are being evaluated.

A single fatality and one possible case of progressive Multifocal leukoencephalopathy (PML) have been reported in patients receiving Tysabri for MS. However, this adverse effect was not reported when trials were conducted before the marketing phase. Post-marketing studies have facilitated the rapid reporting and response to this new information.

Because Tysabri was just recently approved, these patients have only received at most a few doses of Tysabri and the FDA says it will maintain a close contact with the company during the process to study the relationship between Tysabri and the two serious adverse events.



Advertisement
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All